Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease

Antiviral Therapy

Volumn 16, Issue 1, 2011, Pages 89-98

  Araya, Natsumi ^a   Takahashi, Katsunori ^a   Sato, Tomoo ^a   Nakamura, Tatsufumi ^b   Sawa, Chika ^a   Hasegawa, Daisuke ^a   Ando, Hitoshi ^a   Aratani, Satoko ^a   Yagishita, Naoko ^a   Fujii, Ryoji ^a   Oka, Hiroshi ^a   Nishioka, Kusuki ^c   Nakajima, Toshihiro ^c   Mori, Naoki ^d   Yamano, Yoshihisa ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FUCOIDIN; VIRUS DNA;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DIARRHEA; FEMALE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOCOMPETENT CELL; MALE; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PROVIRUS; SPINAL CORD DISEASE; TROPICAL SPASTIC PARAPARESIS; VIRUS LOAD;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; DENDRITIC CELLS; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; GENES, REPORTER; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LUCIFERASES; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; PARAPARESIS, TROPICAL SPASTIC; POLYSACCHARIDES; PROVIRUSES; SEAWEED; VIRAL LOAD;

EID: 79951500470     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1699     Document Type: Article

References (34)

1. de Thé G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993; 9:381-386.
2. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50:481-492. (Pubitemid 8180432)
3. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2:407-410. (Pubitemid 15231248)
4. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1:1031-1032. (Pubitemid 16102987)
5. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4:586-593. (Pubitemid 29042065)
6. Nagai M, Yamano Y, Brennan MB, Mora CA, Jacobson S. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol 2001; 50:807-812. (Pubitemid 33116143)
7. Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 2002; 99:88-94.
8. Okayama A, Stuver S, Matsuoka M, et al. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer 2004; 110:621-625. (Pubitemid 38658030)
9. Mahony MC, Oehninger S, Clark GF, et al. Fucoidan inhibits the zona pellucid-induced acrosome reaction in human spermatozoa. Contraception 1991; 44:657-665.
10. Baba M, Snoeck R, Pauwels R, de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 1988; 32:1742-1745. (Pubitemid 18267628)
11. Zacharopoulos VR, Phillips DM. Cell-mediated HTLV-1 infection of a cervix-derived epithelial cell line. Microb Pathog 1997; 23:225-233. (Pubitemid 27448525)
12. Romanos MTV, Andrada-Serpa MJ, Mourao PAS, et al. A sulphated fucan from the Laminaria abyssalis inhibits the human T cell lymphotropic virus type 1- induced syncytium formation in HeLa cells. Antivir Chem Chemother 2002; 13:219-221. (Pubitemid 36733661)
13. Haneji K, Matsuda T, Tomita M, et al. Fucoidan extracted from Cladosiphon okamuranus Tokida induces apoptosis of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Nutr Cancer 2005; 52:189-201. (Pubitemid 41579761)
14. Yoshida A, Piroozmand A, Sakurai A, et al. Establishment of a biological assay system for human retroviral protease activity. Microbes Infect 2005; 7:820-824. (Pubitemid 40826647)
15. Fukushima N, Nakamura T, Nishiura Y, Ida H, Aramaki T, Eguchi K. HTLV-I production based on activation of integrin/ligand signaling in HTLV-I-infected T cell lines derived from HAM/TSP patients. Intervirology 2008; 51:123-129. (Pubitemid 352009471)
16. Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In Blattner WA (Editor). Human Retrovirology: HTLV. New York: Raven Press 1990; pp. 191-197.
17. Nakagawa M, Izumo S, Ijichi S, et al. HTLV-I associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995; 1:50-61.
18. + cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis 2001; 183:197-205.
19. Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299:1713-1716. (Pubitemid 36337193)
20. Bangham CR. HTLV-1 infection: role of CTL efficiency. Blood 2008; 112:2176-2177.
21. Azakami K, Sato T, Araya N, et al. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 2009; 114:3208-3215.
22. Bangham CR, Osame M. Cellular immune response to HTLV-1. Oncogene 2005; 24:6035-6046. (Pubitemid 43086121)
23. Oh U, Yamano Y, Mora CA, et al. Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol 2005; 57:526-534. (Pubitemid 40471162)
24. Nomoto M, Utatsu Y, Soejima Y, Osame M. Neopterin in cerebrospinal fluid: a useful marker for diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis. Neurology 1991; 41:457.
25. Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2003; 9:29-35. (Pubitemid 36372543)
26. Taylor GP, Tosswill JH, Matutes E, et al. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr 1999; 22:92-100. (Pubitemid 29486915)
27. Nose H, Saito M, Usuku K, et al. Clinical symptoms and the odds of human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in healthy virus carriers: application of best-fit logistic regression equation based on host genotype, age, and provirus load. J Neurovirol 2006; 12:171-177. (Pubitemid 44574592)
28. + T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J Exp Med 2004; 199:1367-1377.
29. + T cells in a retrovirus-associated neuroinflammatory disorder. PLoS ONE 2009; 4:e6517.
30. Saito M, Nakagawa M, Kaseda S, et al. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2004; 189:29-40. (Pubitemid 38122326)
31. Nishiura Y, Nakamura T, Fukushima N, et al. Disulfide-mediated apoptosis of human T-lymphotropic virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther 2009; 14:533-542.
32. Sonoda J, Koriyama C, Yamamoto S, et al. HTLV-1 provirus load in peripheral blood lymphocytes of HTLV-1 carriers is diminished by green tea drinking. Cancer Sci 2004; 95:596-601. (Pubitemid 39089642)
33. Taylor GP, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology 2006; 3:63.
34. Li HC, Yashiki S, Sonoda J, et al. Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res 2000; 91:34-40. (Pubitemid 30128935)